Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MEDI5752 in advanced solid tumors
NL-OMON54211Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of volrustomig in Nonhematologic neoplasms, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) (9 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability in dose-escalation, Maximum tolerated dose / optimal biological dose / highest protocol-defined dose and 2 more. Started Mar 2022; status: recruiting.
02
Drugs
volrustomig
03
Conditions
Nonhematologic neoplasmsrenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54211.